OCUMENSION-B (01477) has published its interim results for the six months ended June 30, 2026. The group recorded revenue of 424 million yuan, representing a year-on-year increase of 44.1%. The adjusted net loss stood at 57.523 million yuan, a decrease of 46.74% compared to the same period last year, with a loss per share of 0.12 yuan.

According to the announcement, the substantial revenue growth was primarily attributed to a significant increase in income generated from the sale of ophthalmic products, including YUTIQ®, XALATAN®, XALACOM®, Allergodil®, and products acquired and licensed from Alcon under the Alcon transaction. Additionally, sales-based royalty income saw a notable rise, mainly driven by the successful commercialization of Buruijing®.